Silk bioprotein wound dressing for double‑incision mastectomy
Official title: The Utility of Silk Bioprotein as a Wound Dressing in Female-to-Male Double-Incision Mastectomy
Run by Indiana University · NCT06921148 · Data updated 2026-11-12
This project will test whether a silk bioprotein dressing reduces adhesive‑related skin injuries and other wound problems compared with Dermabond/Prineo in adults having double‑incision mastectomy for gender‑affirming surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Indiana University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Indianapolis, Indiana) |
| Status | Recruiting |
| Started | September 11, 2025 |
| Main results expected | April 30, 2028 |
| Study ends | June 14, 2028 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT06921148 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (18+) scheduled for double‑incision bilateral mastectomy for female‑to‑male gender‑affirmation at Indiana University Health who do not meet exclusion criteria.
✕Probably not a fit
Patients with prior breast surgery or chest radiation, active conditions that impair wound healing, or known allergies to the dressings are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults undergoing double‑incision bilateral mastectomy for female‑to‑male gender‑affirming surgery at Indiana University Health will receive either a silk bioprotein dressing (Sylk) or the standard Dermabond/Prineo dressing applied to their surgical incisions. Clinical staff will monitor participants during routine postoperative visits for adhesive‑related skin injuries, wound dehiscence, surgical‑site infection, and healing outcomes, and record any adverse reactions. Key exclusion criteria include prior breast surgery or radiation, a history of breast cancer, significant comorbidities that impair healing, or known allergies to either dressing. The trial compares the incidence and severity of skin reactions and wound complications between the two dressing groups to determine whether silk offers a safer alternative.
Why it matters
Potential benefit: If successful, the silk dressing could reduce adhesive‑related skin injuries and other wound complications, improving healing, comfort, and cosmetic outcomes after double‑incision mastectomy.
How similar studies have gone: Silk bioprotein has supportive preclinical and clinical data in tissue engineering, and a small number of prior clinical reports have shown safety and potential usefulness as a surgical dressing, but its use for this procedure is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over the age of 18 undergoing double-incision bilateral mastectomy for female-to-male gender affirming surgery with the principal investigator. * Physicians will be plastic surgeons in the IU Health system Exclusion Criteria: * Patients with a history of breast cancer. * Patients with prior history of breast surgery. * Patients with a prior history of radiation to the chest wall/breast. * Patients with medical comorbidities that predispose to poor wound healing (diabetes, nutritional deficiency, smoking, inflammatory disease, chronic steroid use, immune deficiency, morbid obesity). * Patients with a history of documented allergic reaction to Dermabond/Prineo or Silk Bioprotein dressing, or any of the constituents that make up these dressings. * Significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study. * Physicians not in the IU Health system will not be included.
Where it's running
-
Indiana University Health
Indianapolis, Indiana, United States Recruiting
Study contacts
- Principal investigator: Ivan Hadad, MD — Indiana University
- Study coordinator: Ivan Hadad, MD
- Email: ihadad@iu.edu
- Phone: (317) 944-5000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lactoferrin Gel for Healing and Implant Stability in Immediate Mandibular Molars
A 4% bovine lactoferrin nanohydrogel is being tested to see if it helps soft tissue and bone heal better and improve implant stability after immediate mandibular molar implants.
-
Curcumin topical spray for healing after a first molar extraction
This study tests whether a curcumin spray applied to the extraction site helps healing and reduces pain compared with chlorhexidine spray or standard care in healthy adults undergoing a first molar extraction.
-
Calcaneal Bone Marrow Cells in Foot/Ankle Surgery Patients
This observational study tests whether routine preoperative blood tests relate to the quality and behavior of mesenchymal stem cells from calcaneal bone marrow in adults undergoing foot or ankle surgery.
-
Obesity and normal-weight healing after gum graft surgery using collagen plug or PRF
This study tests whether healing after a gum graft differs by weight class (obese vs. normal weight) and compares platelet-rich fibrin clot to the standard collagen plug.
-
Early Wound Healing and Outcomes of Regenerative Periodontal Surgery
This study looks to see if healing in the first 1–2 weeks after periodontal regenerative surgery can predict how well the treatment works at 12 months in people with advanced periodontitis.
-
Ozoaqua scar care after open abdominal surgery compared with standard care
This study tests if adding Ozoaqua products after open abdominal surgery improves the scar quality at 3 months compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.